Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Pioneering
personalized medicine
in epigenetics

Oryzon now

4 January 2021

ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

Read more
17 December 2020

ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry

Read more
7 December 2020

ORYZON presents new robust Phase II iadademstat efficacy data in AML at ASH-2020

Read more

ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders

About us
Epigenetics

Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.

More info
Therapeutic programs

ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.

More info
Latest News
  • 4 January 2021

    ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

    • Read more about ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021
  • 17 December 2020

    ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry

    • Read more about ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry
  • 7 December 2020

    ORYZON presents new robust Phase II iadademstat efficacy data in AML at ASH-2020

    • Read more about ORYZON presents new robust Phase II iadademstat efficacy data in AML at ASH-2020
All News
Upcoming events
  • 4-22 January 2021

    ACCESS CHINA Forum @JPM Week 2021

    • More details about ACCESS CHINA Forum @JPM Week 2021
  • 26-28 January 2021

    Edison’s Open House – Global Healthcare 2021

    • More details about Edison’s Open House – Global Healthcare 2021
All Events
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy